title: [Salidroside improves pulmonary fibrosis by down-regulation of cathepsin B and NF-κBp65 in rats].
abstract: To investigate the mechanism of salidroside in improvement of pulmonary fibrosis in rats.  Methods: SD rats were subjected to 6 groups: a blank group, a model group, a pirfenidone group, a high-dose salidroside group, a middle-dose salidroside group, and a low-dose salidroside group. The contents of ALB, ALP, LDH, PC-III and COL4, and the expression levels of cathepsin B (CB) and NF-κBp65 in the 6 groups were analyzed.  Results: Lung coefficient and oxygen partial pressure in the blank group were lower than those in the model group (P<0.05). Compared with the model group, lung coefficients in the pirfenidone group, the high-dose salidroside group, the middle-dose salidroside group, and the low-dose salidroside group were decreased, while oxygen partial pressures were statistically increased (P<0.05). The contents of ALB, ALP and LDH in the model group were statistically increased (P<0.05) in a dose-dependent manner. Compared with the blank group, the contents of GSH, HYP, PC-III and COL4, and the expression levels of CB and NF-κBp65 in the model group were significantly increased (P<0.05), which were attenuated by alidroside in a dose-dependent manner (P<0.05).  Conclusion: Salidroside can improve pulmonary fibrosis in rats, and the mechanism may be related to reduce the expression of CB and NF-κBp65.
authors.affiliation: Department of Respiration, Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences, Chengdu 610072, China syyliudoc@sina.com.
authors.forename: Xingren
authors.initials: X
authors.lastname: Liu
authors.affiliation: Department of Oncology, Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences, Chengdu 610072, China.
authors.forename: Yifeng
authors.initials: Y
authors.lastname: Bai
authors.affiliation: Department of Oncology, Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences, Chengdu 610072, China.
authors.forename: Liang
authors.initials: L
authors.lastname: Liang
authors.affiliation: Department of Traditional Chinese Medicine, Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences, Chengdu 610072, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Feng
authors.affiliation: Department of Nephrology, Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences, Chengdu 610072, China.
authors.forename: Fei
authors.initials: F
authors.lastname: Deng
mesh_terms: D000818:Animals; D002401:Cathepsin B / Q000187:drug effects / Q000378:metabolism; D015536:Down-Regulation; D005960:Glucosides / Q000494:pharmacology* / Q000627:therapeutic use*; D008168:Lung / Q000737:chemistry; D016328:NF-kappa B / Q000187:drug effects / Q000378:metabolism; D010092:Oximetry; D010100:Oxygen / Q000097:blood; D010636:Phenols / Q000494:pharmacology* / Q000627:therapeutic use*; D011658:Pulmonary Fibrosis / Q000628:therapy*; D011659:Pulmonary Gas Exchange / Q000187:drug effects; D011728:Pyridones; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D005960:Glucosides; D016328:NF-kappa B; D010636:Phenols; D011728:Pyridones; C093844:pirfenidone; D002401:Cathepsin B; C009172:rhodioloside; D010100:Oxygen